ECYT
Endocyte, Inc. Common Stock
ECYT
ECYT
Delisted
ECYT was delisted on the 20th of December, 2018.
75 hedge funds and large institutions have $18.4M invested in Endocyte, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 28 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
75
Holders Change
-7
Holders Change %
-8.54%
% of All Funds
1.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
16
Reduced
28
Closed
22
Calls
$147K
Puts
$457K
Net Calls
-$310K
Net Calls Change
-$564K
Top Buyers
| 1 |
Morgan Stanley
New York
|
$811K |
| 2 |
Millennium Management
New York
|
$1.04M |
| 3 |
Goldman Sachs
New York
|
$646K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
$287K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
$477K |
Top Sellers
| 1 |
BlackRock
New York
|
$534K |
| 2 |
State Street
Boston,
Massachusetts
|
$27K |
| 3 |
JPMorgan Chase & Co
New York
|
$364K |
| 4 |
Northern Trust
Chicago,
Illinois
|
$119K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
$1.99M |
